Stoke Therapeutics Reports Q3 2026 Financial Results and Clinical Pipeline Progress
Stoke Therapeutics (STOK) reported third-quarter revenue of $11.3 million, up from $10.6 million in the prior year, driven by collaboration and licensing agreements with Acadia and Biogen. Despite the revenue growth, the company reported a net loss of $73.6 million, largely due to increased research and development spending on its zorevunersen program and launch readiness expenditures. The company highlighted significant progress in its Phase III EMPEROR study for Dravet syndrome, noting that enrollment has exceeded targets with 162 patients across the U.S., U.K., and Japan. Clinical data collection is ongoing, with a primary endpoint readout expected in Q3 2027. Additionally, Stoke's STK-002 program for Autosomal Dominant Optic Atrophy (ADOA) continues to advance through Phase I trials. With $358.8 million in cash and marketable securities, management expects current funding to support operations into early 2028. While clinical milestones are being met, CEO Ian Smith noted potential valuation challenges regarding reimbursement and pricing within European single-payer markets.
Topics: cash runway clinical trial progress net loss R&D expenses revenue